Latest news with #E.AndersKolb
Yahoo
02-06-2025
- Business
- Yahoo
Subaru Celebrates Ten Years Partnering With the Leukemia & Lymphoma Society To Support Nearly 500,000 Cancer Patients and Families Nationwide
CAMDEN, NJ / / June 2, 2025 / Automaker provides relief and support through funding, physical donations, and messages of hope Subaru of America, Inc. today announced a major milestone, marking the tenth consecutive year of partnering with The Leukemia & Lymphoma Society® (LLS) as part of its Subaru Loves to Care® initiative. As the largest automotive donor to LLS, Subaru and its retailers are committed to supporting children and families affected by blood cancer, and by the end of 2025, will have helped nearly 500,000 cancer patients nationwide. The treatment and recovery for blood cancer patients can be long, difficult, and emotionally draining, often leaving individuals feeling isolated and physically weakened. In response, Subaru and its retailers bring warmth and compassion through the delivery of custom heart-shaped blankets, curated care kits, and handwritten messages of hope. These gestures provide valuable relief and reinforce the importance of community support. Alan Bethke, Senior Vice President of Marketing at Subaru of America, Inc.: "A decade of working together on Subaru Loves to Care has only served to reinforce how meaningful a personal touch can be for those facing cancer. Hand in hand with our retailers and The Leukemia & Lymphoma Society, we remain committed to delivering warmth, love, and comfort during some of life's most difficult moments. This partnership helps make a difference by reminding cancer patients how many people are rooting for them." Throughout June, over 630 participating retailers across the country will continue sharing hope by delivering blankets and personal messages to cancer patients in local hospitals. Additionally, 370 of those participating retailers will provide care kits to offer added comfort throughout treatment and recovery. Through these continued efforts, Subaru strengthens its promise to be More Than a Car Company®, one blanket and note at a time. In addition to donating and delivering blankets, messages of hope, and care kits, participating retailers are also contributing to The Leukemia & Lymphoma Society's Urgent Need Pediatric, Adolescent and Young Adult Fund. The fund provides financial assistance to young blood cancer patients and their families to help with non-medical related expenses, from groceries to transportation, housing and more. Along with these contributions from retailers, Subaru will match donations made through during Subaru Loves to Care between June 1 and 30, 2025, up to $100,000 in total. E. Anders Kolb, M.D., President and CEO of The Leukemia & Lymphoma Society: "Thoughtful gestures like blankets and handwritten notes from Subaru and its retailers offer real comfort, love, and encouragement during treatment, especially for children. When I think about the number of lives we have touched over the past ten years, it fills my heart to know that so many patients were reminded that they're not alone. That simple act of kindness is one that leaves a lasting effect." Those looking to write messages of hope for patients in their community are invited to visit their local Subaru retailer. For more information on Subaru Loves to Care, visit and follow #SubaruLovestoCare on social media to see this initiative in action. To learn more about the Subaru Love Promise, visit ### About Subaru of America, of America, Inc. (SOA) is an indirect wholly owned subsidiary of Subaru Corporation of Japan. Headquartered in Camden, N.J., the company markets and distributes Subaru vehicles, parts, and accessories through a network of about 640 retailers across the United States. All Subaru products are manufactured in zero-landfill plants, including Subaru of Indiana Automotive, Inc., the only U.S. automobile manufacturing plant designated a backyard wildlife habitat by the National Wildlife Federation. SOA is guided by the Subaru Love Promise, which is the company's vision to show love and respect to everyone and to support its communities and customers nationwide. Over the past 20 years, SOA and the SOA Foundation have donated more than $320 million to causes the Subaru family cares about, and its employees have logged over 100,000 volunteer hours. Subaru is dedicated to being More Than a Car Company® and to making the world a better place. For additional information, visit Follow us on Facebook, Instagram, LinkedIn, TikTok, and YouTube. About The Leukemia & Lymphoma SocietyThe Leukemia & Lymphoma Society® (LLS) is the global leader and innovator in creating a world without blood cancer. The LLS mission: Cure blood cancer and improve the quality of life of all patients and their families. LLS is focused on accelerating research, providing free support and services, and advocating for policies to ensure access to quality, affordable care. For more than 75 years, LLS has been helping blood cancer patients live longer, better lives. To learn more, visit Patients can contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 9 p.m. ET. Connect with us on Facebook, X, Instagram, LinkedIn and TikTok. Media Contacts Diane AntonCorporate Communications Manager(856) 488-5093danton@ Adam LeiterCorporate Communications Specialist(856) 488-8668aleiter@ Subaru of America, Inc. partners with The Leukemia & Lymphoma Society® (LLS) for the tenth consecutive year as part of the Subaru Loves to Care® initiative. Subaru is the largest automotive donor to LLS, and by the end of 2025, Subaru and its retailers will have supported nearly 500,000 cancer patients around the country with funding, blanket donations, and messages of hope through this continued partnership. View additional multimedia and more ESG storytelling from Subaru of America on Contact Info:Spokesperson: Subaru of AmericaWebsite: Email: info@ SOURCE: Subaru of America View the original press release on ACCESS Newswire Sign in to access your portfolio
Associated Press
21-04-2025
- Health
- Associated Press
LLS Expands its Global Master Trial for Hard-To-Treat Leukemias in Children
Marks the First-Ever Global Pediatric Trial for Menin Inhibitors The PedAL (Pediatric Acute Leukemia) Master Trial is at the heart of LLS's Dare to Dream Project to transform treatment and care for kids with blood cancer WASHINGTON, April 21, 2025 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) announced today the first pediatric patient has received treatment in a new subtrial of its Pediatric Acute Leukemia (PedAL) Master Clinical Trial ( NCT04726241 ). PedAL is a first-of-its-kind integrated worldwide master trial that tests multiple targeted drugs simultaneously to accelerate treatments for leukemia, the most common childhood cancer. Infants and children with specific types of relapsed/refractory leukemia (KMT2A-rearranged, NUP98-rearranged, or NPM1-mutant acute leukemia) are now eligible to enroll in the subtrial, which is investigating a combination of chemotherapy and a menin inhibitor. This subtrial involves pediatric patients with some of the most common and hardest-to-treat leukemias. In fact, 80% of infants with acute lymphoblastic leukemia have a genetic rearrangement of the KMT2A gene. About 40% of infants with acute myeloid leukemia have one of the three specific types of leukemia that the trial's treatment targets1. Menin inhibitors are a new and promising class of drugs that block the interaction between other proteins and the menin protein. Research has shown that the menin protein is responsible for driving progression of certain types of leukemia. The new subtrial is open in North America at Children's Hospital of Philadelphia, Cincinnati Children's Hospital, St. Jude Children's Research Hospital, Memorial Sloan Kettering Cancer Center, Lurie Children's Hospital of Chicago and SickKids - The Hospital for Sick Children in Toronto. Global trial sites are open in Spain, the Netherlands, France and Austria. 'It is rare for a trial to be so ambitious and forward thinking about the needs of children while studies in adults are still ongoing. The new subtrial is evaluating the safety, efficacy and dosing for the treatment of certain acute leukemias in pediatric patients,' says E. Anders Kolb, M.D. President and Chief Executive Officer of The Leukemia & Lymphoma Society. 'Historically, cancer treatments have been evaluated in adults first and if successful, then children. This has resulted in a nearly decade-long delay between when therapies are first available for adults compared to children.' The new subtrial brings LLS one step closer to achieving its bold goal: By 2040, LLS will enable patients with blood cancer to gain more than one million years of life. New trial expands on PedAL, builds on success of LLS's Dare to Dream Project PedAL launched in 2022 with one treatment subtrial investigating venetoclax. That trial is now open at approximately 80 clinical sites in 19 countries across the globe. Enrollment in the treatment trials begins with the robust PedAL screening trial ( NCT04726241 ), open in 179 sites in the United States, Canada, Australia and New Zealand. To date, the screening trial has enrolled almost 450 children to identify their unique tumor biology and help match them to any targeted treatment clinical trial they are eligible for, whether in or outside of PedAL. Because blood cancers are more common in adults, there is a larger incentive for new treatments to be developed in that population, and progress for pediatric acute leukemia has fallen behind. PedAL is changing this paradigm. A delay in research and the development of therapies for children with aggressive forms of cancer threatens their survival. Today, leukemia is the second leading cause of cancer deaths in children. And for children who survive, 80% develop life-altering and chronic health issues from their treatment. 'More children are being diagnosed with leukemia today than ever before,' says Kim Schuetz, an oncology nurse, an LLS Dare to Dream Ambassador and mother to Austin, who was diagnosed with acute lymphoblastic leukemia in 2011. 'We need to study more treatment options for these children. Through Dare to Dream, we're striving to transform care, so they don't experience a laundry list of life-long health issues and the possibility of developing secondary cancers because of treatment from standard therapies, such as harmful chemotherapies.' LLS has supported the development of menin inhibitors over two decades In the early 2000s, LLS provided funding to a group of bright scientific investigators, which led them to discover the menin protein inside cancer cells and its role in the devastating effects of certain forms of leukemia. Over the next several years, LLS provided more than $6 million through its venture philanthropy program, the Therapy Acceleration Program (TAP), to scientists at the University of Michigan. They discovered small molecule inhibitors of the interaction of two proteins, menin and KMT2A/MLL, that, when fused together, drive progression of AML. With TAP funding, the scientists demonstrated the activity of their compounds in the laboratory setting. To facilitate translation of the scientists' progress in the laboratory to the clinic, LLS introduced the scientists to a clinical-stage biopharmaceutical company. Helping children with blood cancer survive and thrive Dare to Dream is transforming treatment and care for kids with blood cancer, so they not only survive but thrive after treatment. PedAL is an integral part of LLS's Dare to Dream Project along with support services, advocacy efforts and funding for blood cancer research: 'The successes of the Dare to Dream Project, now and in the future, positions us well to reach our bold goal of enabling blood cancer patients to gain more than one million years of life by 2040,' says Gwen Nichols, M.D., Chief Medical Officer of LLS. 'Advances in treatment and care, spearheaded by Dare to Dream, will give even more children a chance to grow and thrive into adulthood.' People can donate to LLS at any time. From May 12-16, all donations made to LLS will go directly to The Dare to Dream Project. Interested in donating to The Dare to Dream Project? Visit this link for more information. About The Leukemia & Lymphoma Society The Leukemia & Lymphoma Society® (LLS) is the global leader in the fight against blood cancer. The LLS mission: Cure blood cancer and improve the quality of life of all patients and their families. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care. Founded in 1949, LLS has regions throughout the United States and Canada. To learn more, visit Patients should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 9 p.m. ET. For additional information, visit Follow us on Facebook, X, Instagram, LinkedIn and TikTok. About The Dare to Dream Project Dare to Dream exists to transform treatment and care for kids with blood cancer. Because kids are different and need to be treated differently, Dare to Dream funds groundbreaking research and the LLS PedAL Master Clinical Trial as well as expands LLS support services and drives advocacy efforts to help all kids with blood cancers get accessible, affordable, quality healthcare. LLS proudly and gratefully acknowledges all those contributing to the LLS mission, including corporate partners Walgreens, Valvoline™ Global Operations, The Wawa Foundation, and Subaru of America, Inc. and its retailers who have each pledged over $1 million to Dare to Dream. LLS also recognizes Sarah Asma and the Moore family; The Don & Lorraine Freeberg Foundation; The Harry T. Mangurian Jr. Foundation; Norcross Foundation, Inc.; Joan and Paul Rubschlager; and The Bobby Zahurak Pediatric AML Research and Patient Support Fund for their outstanding contributions to Dare to Dream. For more information about Dare to Dream, including resources for patients and their families, trial details, and eligibility, visit: About LLS PedAL As part of LLS's Dare to Dream Project, the Pediatric Acute Leukemia Master Trial (PedAL) is the first-of-its-kind global master clinical trial for pediatric acute leukemia patients that will fundamentally change how children are treated. Prior to enrolling in therapeutic trials, patients enroll in the PedAL Screening Trial ( NCT04726241 ) to identify the unique tumor biology of each child's cancer and help them to match with the most promising treatment. The Screening Trial is currently open at multiple sites in the United States, Canada, Australia, and New Zealand. At this time, two PedAL therapeutic trials are open and actively enrolling patients in the U.S., Canada, Australia, New Zealand, Japan, and Europe, with more therapeutic trials planned for global execution. To learn more about PedAL, visit PedAL would not be possible without the support of major foundation donors such as Gateway for Cancer Research, which pledged $1.5 million over three years to support genomic sequencing and flow cytometry, which is being conducted through the PedAL screening trial, and the Lisa Dean Moseley Foundation, which has committed $1.25 million over five years to support the PedAL Principal Investigators Fellowship Program, whose members are leading the PedAL screening trial and therapeutic trials. Media Contact: Sandra Salviejo Senior Director, Communications [email protected] Reference: 1 Juul-Dam KL et al. European Journal of Medical Genetics 2023 View original content to download multimedia: SOURCE The Leukemia & Lymphoma Society (LLS)
Associated Press
31-01-2025
- Health
- Associated Press
The Leukemia & Lymphoma Society rings Nasdaq bell to mark 75 years of progress and announce its bold goal for the future
The organization will enable blood cancer patients to gain one million years of life by 2040 RYE BROOK, N.Y., Jan. 31, 2025 /PRNewswire/ -- Celebrating its 75th year of progress toward its mission to cure blood cancer and improve the quality of life of all patients and their families, The Leukemia & Lymphoma Society (LLS), founded on this day in New York in 1949, announced a bold goal for the future: to enable blood cancer patients to gain more than one million years of life by 2040. This bold goal, supported by a new organizational strategy, builds on decades of LLS work that is already contributing to longer and better lives for patients with every type of blood cancer all over the world. Gaining one million years of life means more birthdays, graduations, weddings, holidays and memories shared with family and friends. The moment was marked by the ceremonial ringing of the Nasdaq opening bell as a lead-up to World Cancer Day on Feb. 4. Thanks to a gift from The Orokawa Foundation, all donations to LLS on Feb. 4 will be matched dollar-for-dollar up to $75,000 to mark the culmination of LLS's 75-year milestone. 'Every day, blood cancer patients ring the bell marking milestones in their treatment. Thanks to scientific innovation, patient support and advocacy fueled by LLS over 75 years, today we ring the bell for all blood cancer patients – as we announce our bold goal for the future,' said E. Anders Kolb, M.D., president and CEO of LLS. 'Our bold goal represents the additional years of life we can gain through continued innovation and collaboration. We're endeavoring beyond today's achievements to accelerate the pace of discovery and access to care to add one million more years of life on top of our current trajectory,' he said. As the world's leading organization dedicated to ending blood cancer, LLS has already made tremendous strides over the past several decades. LLS has invested more than $1.8 billion in blood cancer research, resulting in treatments that have turned once-fatal blood cancers into manageable chronic conditions and, in many cases, provided cures. LLS takes a comprehensive approach that also includes patient education, support and advocacy, which has helped drive significant progress for blood cancer patients and their families. But there's still more work to be done. LLS's strategy focuses on accelerating cures and treatments, improving healthcare delivery and supporting and empowering every patient in every community. 'If everyone had timely and equitable access to the best treatments available right now, patients would gain even more years of life,' said Gwen Nichols, M.D., chief medical officer of LLS. 'This is why LLS works so hard to give patients and families the financial, educational and emotional support they need to advocate for their best care. We are also a leader in health services research, generating evidence that can be used to improve healthcare practice and policy so more people can benefit from the breakthrough treatments we've funded.' 'To achieve our bold goal, we need the support of everyone,' said Kolb. 'Our work isn't possible without the collaboration of the scientific community, healthcare professionals, policymakers and the generosity of our donors, volunteers and supporters. Together, we can push forward innovations that ultimately save and improve lives.' About The Leukemia & Lymphoma Society (LLS) The Leukemia & Lymphoma Society® (LLS) is the global leader in the fight against blood cancer. The LLS mission: Cure blood cancer and improve the quality of life of all patients and their families. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care. Founded in 1949, LLS has regions throughout the United States and Canada. To learn more, visit Patients should contact the Information Resource Center at (800) 955-4572, Mon through Fri, 9 a.m. to 9 p.m. ET.
